Filtered By:
Education: Study
Nutrition: Vitamin K

This page shows you your search results in order of date. This is page number 13.

Order by Relevance | Date

Total 1097 results found since Jan 2013.

Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis
Conclusions Our meta-analysis provides comprehensive economic evidence that allows policy makers to generalise cost-effectiveness data to their local context. All DOACs may be cost-effective compared with VKA in HICs with TPP perspective. The pooling results produced moderate to high heterogeneity particularly in UMICs. Further studies are required to inform UMICs with SP. PROSPERO registeration number CRD 42019146610.
Source: Evidence-Based Medicine - July 28, 2022 Category: Internal Medicine Authors: Noviyani, R., Youngkong, S., Nathisuwan, S., Bagepally, B. S., Chaikledkaew, U., Chaiyakunapruk, N., McKay, G., Sritara, P., Attia, J., Thakkinstian, A. Tags: Open access Evidence synthesis Source Type: research

Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention
ConclusionsCombination of low-dose prasugrel and DOAC was associated with lower incidence of MI, ischemic stroke, and blood transfusion. Low-dose prasugrel may be feasible as part of triple therapy in patients undergoing PCI.
Source: PLoS One - July 28, 2022 Category: Biomedical Science Authors: Hideki Kitahara Source Type: research

Systematic review of efficacy of direct oral anticoagulants and vitamin K antagonists in left ventricular thrombus
ConclusionsCompared with VKAs, DOACs significantly reduce the risk of bleeding events and stroke in LVT patients, but mortality was similar in both groups. The advantages are apparent not only in patients belonging to the predominantly white residential areas such as North American and European regions but also in patients with LVT due to IHD. DOACs show promising effects in treating LVT compared with VKAs.
Source: ESC Heart Failure - July 27, 2022 Category: Cardiology Authors: Lei Huang, Yuan Tan, Yilong Pan Tags: Original Article Source Type: research

Serum or Plasma for Quantification of Direct Oral Anticoagulants?
Background: Direct oral anticoagulants are increasingly replacing vitamin K antagonists for prevention of stroke in patients with atrial fibrillation, partly owing to the lack of a need for routine monitoring. Therapeutic drug monitoring may still be warranted under certain circumstances. It is generally assumed that serum and plasma can be interchangeably used for this purpose. The aim of this study was to investigate possible differences between the serum, citrate-plasma, and ethylenediaminetetraacetic acid (EDTA)-plasma concentrations of apixaban and rivaroxaban in a larger patient group and their relation to factor...
Source: Therapeutic Drug Monitoring - July 20, 2022 Category: Drugs & Pharmacology Tags: Original Article Source Type: research

Association between Acid-Suppressive Drugs and Clinical Outcomes in Patients with Nonvalvular Atrial Fibrillation
ConclusionsASDs were significantly associated with all-cause mortality in patients with NVAF taking OACs.
Source: Drugs in R&D - July 19, 2022 Category: Drugs & Pharmacology Source Type: research

Clinical outcomes in patients receiving edoxaban or phenprocoumon for prevention of stroke in atrial fibrillation: a German real-world cohort study
Appropriate and timely anticoagulant therapy with vitamin K antagonists (VKAs) or non-vitamin K oral antagonists (NOACs) is essential for stroke prevention in non-valvular atrial fibrillation (NVAF). Comparati...
Source: Thrombosis Journal - July 4, 2022 Category: Hematology Authors: Christopher Hohmann, Magnus Lutz, Sheila Vignali, Kathrin Borchert, Karolin Seidel, Sebastian Braun, Stephan Baldus and Michael N äbauer Tags: Research Source Type: research

P73 Real-World Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Patients with Non-Valvular Atrial Fibrillation (NVAF): A Retrospective Cohort Study in Singapore
This study aims to compare the real-world effectiveness and safety between NOAC and warfarin in NVAF patients and assess the potential long-term impact on the healthcare system in Singapore.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: W. Foo, T. Hui, S.K.B. Ong, K.H. Ng Tags: Real-World Evidence for Comparative Effectiveness, Safety and Adherence Evaluations Source Type: research

Use of Oral Anticoagulants and Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke
To the Editor A recent article suggested that the use of non –vitamin K antagonist oral anticoagulants (NOACs) within 7 days of intravenous alteplase was not associated with an increased risk of intracranial hemorrhage. However, we are concerned that some readers may interpret these results as an endorsement of the use of alteplase in patients with acute st roke who were taking NOACs, irrespective of the time frame of last use. Based on dose-finding studies, the drug half-life is 12 hours for apixaban, 11 to 13 hours for rivaroxaban, 10 to 14 hours for edoxaban, and 12 to 17 hours for dabigatran in patients with normal k...
Source: JAMA - June 21, 2022 Category: General Medicine Source Type: research

Anticoagulation for Venous Thromboembolism: Impact on the Risk of Major Adverse Cardiovascular Events
Chest. 2022 Jun 14:S0012-3692(22)01087-X. doi: 10.1016/j.chest.2022.05.038. Online ahead of print.ABSTRACTBACKGROUND: It was recently established that patients who developed venous thromboembolism (VTE) are at increased risk of major adverse cardiovascular events (MACE) than the general population. However, whether the anticoagulation used for VTE influences the risk of MACE remains undescribed.RESEARCH QUESTION: Does the anticoagulant treatment for VTE impact the risk of subsequent MACE?STUDY DESIGN AND METHODS: We included patients from a large prospective cohort, who received only one family of anticoagulant treatment a...
Source: Chest - June 17, 2022 Category: Respiratory Medicine Authors: Steve Raoul Noumegni Raphael Le Mao Claire de Moreuil Cl ément Hoffmann Emmanuelle Le Moigne C écile Tromeur Vincent Mansourati Bahaa Nasr Md Jean-Christophe Gentric Marie Guegan Elise Poulhazan Luc Bressollette Karine Lacut Romain Didier Francis Coutur Source Type: research

Short term outcome after left atrial appendage occlusion with the AMPLATZER Amulet and WATCHMAN device: results from the ORIGINAL registry (saxOnian RegIstry analyzinG and followINg left atrial Appendage cLosure)
Various randomized multicenter studies have shown that percutaneous left atrial appendage closure (LAAC) is not inferior in stroke prevention compared to vitamin K antagonists (VKA) and can be performed safely...
Source: BMC Cardiovascular Disorders - June 16, 2022 Category: Cardiology Authors: Lucie Kretzler, Christoph Mues, Carsten Wunderlich, Anke Langbein, S. G. Spitzer, Ulrich Gerk, Sebastian Schellong, Thomas Ketteler, Hans Neuser, Marcus Schwefer, Ruth Strasser, Karim Ibrahim, Steffen Schoen and Marian Christoph Tags: Research Source Type: research

Comparison of prognostic impact of anticoagulants in heart failure patients with atrial fibrillation and renal dysfunction: direct oral anticoagulants versus vitamin K antagonists
AbstractAlthough high thromboembolic risk was assumed in elderly patients with heart failure (HF) and atrial fibrillation (AF), inadequate control of prothrombin time/international normalized ratio was often observed in patients using vitamin K antagonists (VKAs). We hypothesized that patients treated with direct oral anticoagulants (DOAC) would have a better outcome than those treated with VKAs. The aim of this study was to compare the efficacies of DOACs and VKAs in elderly patients with HF and AF. We retrospectively analyzed data from a multicenter, prospective observational cohort study. A total of 1036 patients who we...
Source: Heart and Vessels - June 4, 2022 Category: Cardiology Source Type: research

Association of Gender With Clinical Outcomes in a Contemporary Cohort of Patients With Atrial Fibrillation Receiving Oral Anticoagulants
CONCLUSIONS: In contemporary anticoagulation for AF, SSE and major bleeding risks did not differ between sexes. However, women showed a lower risk of all-cause death rate than men, indicating that the use of oral anticoagulants for treating AF in females does not appear to be a risk factor for adverse clinical events.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02786095.PMID:35656931 | DOI:10.4070/kcj.2021.0399
Source: Korean Circulation Journal - June 3, 2022 Category: Cardiology Authors: Minjeong Kim Jun Kim Jin-Bae Kim Junbeom Park Jin-Kyu Park Ki-Woon Kang Jaemin Shim Eue-Keun Choi Young Soo Lee Hyung Wook Park Boyoung Joung Source Type: research